Login to Your Account



Rxi lays foundation for Mirimmune buy

By Michael Fitzhugh
Staff Writer

Wednesday, October 12, 2016

Rxi Pharmaceuticals Corp. negotiated an exclusive option to acquire privately held cancer immunotherapy developer Mirimmune Inc.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription